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with first oBP prescription (index event) between January 2004–December 2007, 
≥ 50 years of age, with no history of cancer and a minimum of 12 months’ data 
before and 6 months’ after the index event. Follow-up for any osteoporotic frac-
ture was until December 2008. Persistence was defined as duration of continuous 
oBP use with no gaps > 3 months; compliance was assessed using the medica-
tion possession ratio (MPR; proportion of time with treatment available). HRU 
was evaluated using total primary care contact (including prescriptions), and all 
specialist referrals and hospitalisations. Analyses were stratified by persistence 
and compliance. Results: A total of 21,717 patients were included (mean age, 
73.5 years). Between 2004–2007, fracture rates per patient–year were: 0.14 (95% CI: 
0.12, 0.16; group with MPR < 80%) and 0.11 (0.10, 0.12; MPR ≥ 80%) for patients with 
12–24 months’ persistence vs 0.09 (0.08, 0.10) and 0.07 (0.06, 0.08), respectively, 
for patients with ≥ 36 months’ persistence. Hospitalisation rates were 0.38 (0.34, 
0.42; MPR < 80%) and 0.30 (0.29, 0.32; MPR ≥ 80%) for patients with 12–24 months’ 
persistence vs 0.55 (0.52, 0.59) and 0.18 (0.17, 0.19), respectively, for patients with 
≥ 36 months’ persistence. Among patients who discontinued oBPs and had < 12 
months’ persistence and MPR ≥ 80% before discontinuation, fracture rates were 
0.02 (0.01, 0.03) and 0.09 (0.07, 0.12) in the first and second 6 months following 
discontinuation, respectively, and hospitalisation rates were 0.09 (0.07, 0.11) and 
0.48 (0.42, 0.55), respectively. ConClusions: Outcomes associated with oBPs were 
improved with longer persistence and higher compliance. However, in patients 
with < 12 months’ persistence, protection against fractures and hospitalisation 
diminished 6 months after discontinuation of oBPs.
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objeCtives: The AMPLE trial concluded comparable efficacy of adalimumab (ADA) 
and abatacept (ABA) after one-year methotrexate (MTX) combination treatment for 
rheumatoid arthritis (RA). This study compared effects of adalimumab v. abatacept, 
each in MTX combination, on progressive RA joint damage, adjusting for study 
population characteristics. Methods: Two placebo-controlled trials in early RA, 
PREMIER (ADA+MTX v. MTX) and AGREE (ABA+MTX v. MTX) were selected based on 
design and comparability of enrollment criteria. Patient-level data from PREMIER 
were adjusted, using propensity score weighting, to match average baseline char-
acteristics from AGREE, including RA duration and clinical measures. Radiographic 
progression (RP) was a change in total Sharp score (TSS) > 0 (modified TSS in 
PREMIER and Genant-modified TSS in AGREE). Joint space narrowing (JSN) and joint 
erosion (JE) scores in PREMIER were scaled to proportion with AGREE measures. 
After re-weighting, one-year incremental effects were compared for ADA+MTX vs. 
ABA+MTX, including RP rates, mean JSN and JE score changes from baseline, disease 
activity score (DAS28) remission rates, and American College of Rheumatology 50% 
improvement (ACR50). Results: Compared to AGREE patients, PREMIER patients 
were slightly older, more likely to be Caucasian, had longer RA duration, higher 
C-reactive protein levels, more severe joint damage, and lower functional impair-
ment at baseline. After re-weighting, more ADA+MTX patients had no RP after one 
year compared to ABA+MTX patients (27.0% v. 8.3%; p= 0.02). Mean improvements in 
JSN (-1.41 v. -0.04) and JE (-1.54 v. -0.39) scores from baseline were numerically greater 
with ADA+MTX; statistical significance could not be assessed as standard errors 
were not published for AGREE. No statistically significant differences were observed 
in DAS28 remission rates (p= 0.47) and ACR50 responses (p= 0.72). ConClusions: 
Although both combination therapies yielded similar disease activity measures at 
one year in early RA patients, ADA+MTX offered greater protection against radio-
graphically-confirmed joint damage than ABA+MTX.
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objeCtives: Psoriatic arthritis (PA) is an inflammatory disease affecting joints and 
connective tissues. The anti-tumor necrosis factor (TNF) biologics are increasingly 
being used in patients who have failed traditional disease-modifying antirheu-
matic drugs. Etanercept has shown efficacy in treatment of PA. The objective of 
this study was to conduct meta-analysis and present total evidence for etanercept 
in treatment of PA. Methods: For this meta-analysis we included randomized 
controlled trials (RCTs)evaluating etanercept for the treatment of PS. RCTs study-
ing adult populations with active and progressive PA with an inadequate response 
to previous DMARD therapy were eligible. Trials conducted among PA populations 
with prior experience with anti-TNF agents, including an inadequate response, 
were excluded. A systematic literature search for Etanercept trials was undertaken 
for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was 
collected for the study size, interventions, year, and the three outcomes HAQ, PASI 
and PsARC. For meta-analysis, random effects and fixed effects models were used 
to obtain cumulative statistics. Results: Two RCTs with a total of 131 patients 
were identified. The pooled response rates for Etanercept for PsARC were 75% (95% 
CI 60%-90%), for HAQ were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 
13%-34%). The pooled response rates for placebo for PsARC were 30% (95% CI 26%-
35%), for HAQ were 5% (95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). For 
PsARC the cumulative relative risk with Etanercept versus placebo was 0.40 (95% 
CI 33%-48%). For HAQ, the cumulative relative risk with placebo versus Etanercept 
was 0.08 (95% CI 5%-12%). For PASI, the cumulative relative risk with placebo ver-
sus Etanercept was 0.14 (95% CI 8%-20%). ConClusions: Meta-analysis shows 
Etanercept offers patients with psoriatic arthritis an effective therapeutic option 
for control of their disease.
years and mean days of hospitalization 6.44±4.47 were observed. Disease duration 
of more than 2 years was observed in 336 (55.8%) patients. RA alone, RA with 1 
comorbidity, RA with 2 comorbidities, RA with 3 comorbidities, RA with 4 comorbidi-
ties, RA with 5 comorbidities, were present in 227 (37.7%), 171 (28.4%), 118 (19.6%), 
58 (9.6%), 19 (3.2%), 9 (1.5%) patients respectively. The most common comorbidities 
were diabetes mellitus 114 (18.94%), hypertension 104 (17.28%) and EAM was anemia 
351 (58.30%). ConClusions: Comorbidities and EAM were present in substantial 
proportion of RA patients. Diabetes mellitus, hypertension and anemia were found 
to be most common in our setting. Early diagnosis and management are necessary 
to reduce their impact on therapeutic outcomes in RA.
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objeCtives: To determine the impact of comorbidity burden on real-world health 
care costs of rheumatoid arthritis (RA) patients in Turkey, using nationwide real-
world data. Methods: Study data was obtained from MEDULA (2009-2011). Using 
International Classification of Disease Tenth Revision Clinical Modification (ICD-
10-CM) codes, adult RA patients (ages 18-99) were identified for the identification 
period (June 1, 2010 - December 31, 2010). Patients were required to have two RA 
diagnoses at least 60 days apart, and were grouped as prevalent and incident cases. 
The date of the first RA claim was identified for each patient and designated as 
the index date. Total health care costs were examined over the 12-month period 
following the index date. To control for clinical characteristics, a comorbidity 
index score for each patient during the baseline period was calculated using the 
Elixhauser method. This index is the sum of a comprehensive set of 30 present 
comorbid conditions, and is widely-used in the outcomes research field to deter-
mine patient health status. Individual comorbidities, such as diabetes, respira-
tory diseases, allergy and cardiovascular diseases, were identified using ICD-10 
codes. Results: A total of 2,613 patients met all inclusion criteria (693 incident; 
1,920 prevalent patients). Prevalent patients had higher comorbidity index scores 
relative to incident patients. Nearly 35% of incident and 40% of prevalent patients 
had at least one cardiovascular, diabetic, respiratory, or allergy comorbid condi-
tion prior to the diagnosis. The mean Elixhauser Comorbidity Index score was 
calculated as 5.31 for incident and 5.7 for prevalent patients. Prevalent patients 
with respiratory and cardiovascular comorbid conditions incurred additional 
health care costs of € 302 and € 283 respectively. For incident patients, respiratory 
comorbid conditions increased the health care costs with € 916. ConClusions: 
Respiratory comorbid conditions were associated with health care costs for both 
prevalent and incident RA patients in Turkey.
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objeCtives: To apply a previously validated claims-based severity index for rheu-
matoid arthritis (SIFRA) to prevalent rheumatoid arthritis (RA) groups in Turkey 
and assess the effect of claims-based RA severity on health care costs and bio-
logic use. Methods: The Turkish national health insurance database MEDULA 
(01JUN2009-31DEC2011) was used for the study. Prevalent RA patients were required to 
be age 18-99 with two RA diagnoses ≥ 60 days apart and continuous enrollment 1 year 
pre- (baseline period) and post-index date (follow-up), which was the first RA claim 
during the identification period (01JUN2010-31DEC2010). SIFRA was calculated for the 
baseline period. For the follow-up period, total health care costs and biologic use were 
examined. To determine health care costs, generalized linear models were applied, 
and multivariate logistic regression determined the effect of SIFRA on outcome meas-
ures for biologic use. Results: A total of 1,920 RA patients were identified. The mean 
SIFRA score was 14.21. There was a significant variation in scores across cities. Study 
results confirmed increased biologic use in more severe patients. After adjusting for 
differences in age, gender, region and comorbidity index, patients in the high SIFRA 
tercile were 5.16 times more likely to be prescribed biologics (p< 0.001, confidence 
interval [CI]: 3.46-7.69), and incurred more annual health care costs in the amount of 
€ 2,091 (p< 0.001, CI: € 1,557-€ 2,625) than those in the low SIFRA tercile. ConClusions: 
This study showed that RA severity is a significant determinant of health care costs 
and biologic therapy use. Biologic use was positively correlated with the severity score. 
According to severity scores, the total medical costs of RA patients in Turkey ranged 
from € 1,435 to € 3,275. Since statistically omitting a variable from population models 
provides biased and inconsistent estimates, any comparative effectiveness studies 
on RA treatment should include severity scores in the analysis.
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objeCtives: To assess the impact of persistence and compliance on fracture 
rates and health care resource use (HRU) in women treated with oral bispho-
sphonates (oBPs). Methods: This analysis of the UK CPRD included women 
